XML 37 R21.htm IDEA: XBRL DOCUMENT v3.20.2
Segment and Related Information
 3 Months Ended
Sep. 30, 2020
Segment Reporting [Abstract]  
Segment and Related Information SEGMENT AND RELATED INFORMATIONThe Company’s business is aligned with how the chief operating decision maker reviews performance and makes decisions in managing the Company.  The business units have been aggregated into two reportable segments: (i) diagnostics and (ii) other. The diagnostics segment provides testing and collaborative development of testing that is designed to assess an individual’s risk for developing disease later in life, identify a patient’s likelihood of responding to drug therapy and guide a patient’s dosing to ensure optimal treatment, or assess a patient’s risk of disease progression and disease recurrence. The other segment provides testing products and services to the pharmaceutical, biotechnology and medical research industries, research and development, and clinical services for patients, and includes corporate services such as finance, human resources, legal and information technology.
Segment revenue and operating income (loss) were as follows during the periods presented:
DiagnosticsOtherTotal
Three months ended September 30, 2020
Revenues$130.5 $14.7 $145.2 
Depreciation and amortization16.7 1.0 17.7 
Segment operating loss(0.3)(39.3)(39.6)
Three months ended September 30, 2019
Revenues$170.4 $15.9 $186.3 
Depreciation and amortization16.9 1.3 18.2 
Segment operating income (loss)17.3 (38.2)(20.9)

Three months ended
September 30,
20202019
Total operating loss for reportable segments$(39.6)$(20.9)
Unallocated amounts:
Interest income0.4 0.9 
Interest expense(2.9)(2.9)
Other(1.6)0.6 
Loss from operations before income taxes(43.7)(22.3)
Income tax benefit(28.5)(1.7)
Net loss(15.2)(20.6)
Net loss attributable to non-controlling interest— — 
Net loss attributable to Myriad Genetics, Inc. stockholders$(15.2)$(20.6)